

# Binje Vick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8117612/publications.pdf>

Version: 2024-02-01

22  
papers

1,747  
citations

623574

14  
h-index

713332

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

3405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prime-seq, efficient and powerful bulk RNA sequencing. <i>Genome Biology</i> , 2022, 23, 88.	3.8	31
2	Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 25.	6.9	1
3	Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML. <i>Scientific Reports</i> , 2021, 11, 5838.	1.6	22
4	Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. <i>Nature</i> , 2021, 593, 597-601.	13.7	531
5	In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. <i>Nature Communications</i> , 2021, 12, 5655.	5.8	10
6	Loss of KDM6A confers drug resistance in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 50-62.	3.3	56
7	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. <i>Leukemia</i> , 2020, 34, 1017-1026.	3.3	33
8	Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. <i>Blood</i> , 2020, 136, 1407-1418.	0.6	91
9	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020, 38, 263-278.e6.	7.7	59
10	ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. <i>Oncogene</i> , 2020, 39, 3195-3205.	2.6	18
11	Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice. <i>Haematologica</i> , 2020, 105, 2855-2860.	1.7	15
12	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	0.6	41
13	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. <i>Leukemia</i> , 2019, 33, 1400-1410.	3.3	31
14	Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics. <i>Haematologica</i> , 2019, 104, 546-555.	1.7	10
15	Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice. <i>Leukemia and Lymphoma</i> , 2019, 60, 848-851.	0.6	4
16	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378.	5.8	60
17	The target landscape of clinical kinase drugs. <i>Science</i> , 2017, 358, .	6.0	609
18	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations. <i>Oncotarget</i> , 2017, 8, 108738-108759.	0.8	14

#	ARTICLE	IF	CITATIONS
19	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. PLoS ONE, 2015, 10, e0120925.	1.1	78
20	Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD. Blood, 2015, 126, 1274-1274.	0.6	1
21	Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Oncotarget, 2015, 6, 43508-43528.	0.8	26
22	Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution. Blood, 2013, 122, 49-49.	0.6	2